Home > Press > Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Abstract:
The VenaFlux(TM) Platform Accurately Mimics a Human Capillary
Cellix Ltd., an international provider of microfluidic systems in the emerging field of nano-lifesciences, announced today its worldwide launch of its VenaFlux(TM) Platform. The VenaFlux(TM), the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. The system thereby offers scientists an important and unique tool for drug discovery. The VenaFlux(TM) is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.
Using the VenaFlux(TM), scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.
"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux(TM) accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.
Cellix's technology provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.
About the VenaFlux Platform
The VenaFlux(TM) Platform consists of Cellix's patented Mirus(TM) Nanopump with VenaFluxAssay(TM) software, Vena8(TM) Biochips and DucoCell(TM) analysis software; Carl Zeiss Axiovert(TM) 40 CFL microscope, motorized stage with Z- focus, microscope cage incubator, automated dispenser arm, digital camera for image acquisition and PC. The VenaFlux(TM) Platform can run 8 microcapillaries in 15 minutes, thereby achieving 32 assays in one hour or approximately 1,000 assays per week. The VenaFlux(TM) Platform provides an important new in vitro alternative to expensive animal models while simultaneously cutting down costs on reagents and manpower.
####
About Cellix Ltd.
Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic cellular behavior in vivo for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City.
For more information, please click here
Contacts:
Julia Umlauf
Cellix Ltd.
+1-917-623-4456
Copyright © Cellix Ltd.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
Microfluidics/Nanofluidics
Implantable device shrinks pancreatic tumors: Taming pancreatic cancer with intratumoral immunotherapy April 14th, 2023
Researchers design new inks for 3D-printable wearable bioelectronics: Potential uses include printing electronic tattoos for medical tracking applications August 19th, 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer May 6th, 2022
Nanomedicine
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
Announcements
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |